1. CMS should bolster its oversight of manufacturer-submitted average sales price data to ensure accurate Part B drug payments Publication: Washington, D.C. : U.S. Department of Health and Human Services, Office of Inspector General, December 2022 Subject(s): Cost ControlDrug CostsDrug IndustryGovernment RegulationMedicare Part BPrescription FeesUnited StatesCenters for Medicare & Medicaid Services (U.S.)
2. Manufacturers may need additional guidance to ensure consistent calculations of average sales prices Publication: Washington, D.C. : U.S. Department of Health and Human Services, Office of Inspector General, December 2022 Subject(s): Drug CostsDrug IndustryGovernment RegulationMedicaidMedicare Part BPrescription FeesUnited States
3. Medicare Part B drug payments: impact of price substitutions based on 2021 average sales prices Publication: Washington, D.C. : U.S. Department of Health and Human Services, Office of Inspector General, August 2023 Subject(s): Cost ControlDrug CostsGovernment RegulationMedicare Part BPrescription FeesUnited States
